A retrospective observational study of three migraine cohorts in Canada suggests that acute medications, particularly opioids, are overused and that preventive medications are underused.
1. Intravenous dihydroergotamine (DHE) was found in this retrospective study to be an effective therapeutic option for refractory chronic migraine. 2. DHE was additionally safe for individuals with elevated risk for cardiovascular events and other cardiovascular risk factors. Evidence Rating Level: 2 (Good) Chronic migraine is a debilitating condition that severely impacts the quality of
1. Monthly migraine days were significantly reduced in atogepant 30 mg twice daily and atogepant 60 mg once daily groups compared to placebo. 2. The frequency of acute medication use for headaches was reduced among patients receiving atogepant compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Migraine is a chronic neurological disease affecting